|
Jul 23
|
Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
|
|
Jul 22
|
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic
|
|
Jul 15
|
bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic
|
|
Jul 9
|
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
|
|
Jul 1
|
The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies
|
|
Jun 30
|
Top Research Reports for Meta Platforms, ServiceNow & Booking
|
|
Jun 26
|
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
|
|
Jun 24
|
bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
|
|
May 28
|
bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
|
|
May 20
|
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
|
|
May 20
|
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
|
|
May 8
|
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer
|
|
May 7
|
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering
|
|
May 7
|
bioAffinity Technologies Announces Closing of $3.25 Million Offering
|
|
May 7
|
BioAffinity Technologies announces pricing of $3.25M offering
|
|
May 6
|
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering
|
|
May 6
|
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
|
|
May 6
|
The Zacks Analyst Blog Highlights Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies
|
|
May 5
|
Top Stock Reports for Alphabet, Berkshire Hathaway & Visa
|
|
Apr 7
|
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues
|